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The growing teratoma syndrome (GTS) is deﬁned as a detection of an enlarged mass during or after chemotherapy treatment for
germ cell tumor. We report a case of an 18-year-old girl treated for growing teratoma syndrome after chemotherapy for malignant
germ cell tumor of the ovary associated with peritoneal gliomatosis. Chemotherapy induced normalisation of alpha-fetoprotein
rate whereas there was an enlargement of the mass. Subsequent complete resection was performed, and the patient remained in
good control for 60 months. This clinical picture suggested the diagnosis of “GTS”. This syndrome can lead to confusion with
progression or relapse of a germ cell tumour because of increase in tumour volume during chemotherapy, so it is important to
recognize it.
1.Introduction
The growing teratoma syndrome (GTS) is deﬁned as a detec-
tion of a benign enlarged mass during or after chemotherapy
treatment for germ cell tumor. The diagnosis is based on
threecriteria[1]:increasingsizeoftumorvolumeandmetas-
tasis during chemotherapy for malignant germ cell tumor,
normalization of markers who were initially high during
or after chemotherapy, and the presence in the histological
examination of the postchemotherapy surgical specimen of a
mature teratoma without evidence of malignancy.
This entity was ﬁrst described by Logothetis et al. in
1982 [2]. Other authors had described it under the name of
“chemotherapeutic retroconversion”.
This syndrome occurs in 1.9 to 7.6% of testicular
nonseminomatous germ cell tumors [3], but it appears
exceptionally in patients treatedforovarian germcell tumors
(OGCTs). The peritoneal gliomatosis is deﬁned by the
presence of peritoneal implants, corresponding to nodules of
mature glial tissue in patients with ovarian teratoma.
Wereportacaseofan18-year-oldgirltreatedforgrowing
teratoma syndrome after chemotherapy for malignant germ
cell tumor of the ovary associated with peritoneal gliomato-
sis.
2. Observation
An18-year-old girl, with no previous health problems, no
previous pregnancy, an age of ﬁrst menstruation of 13 years,
presented with a 5-month history of abdominal pain and
increased abdominal volume. Physical examination revealed
a huge abdominopelvic mass, and ultrasound and CT scan
revealed an abdominopelvic mass of 22 × 18cm in diameter,
starting from the right ovary, without lymphadenopathy
or liver metastasis. Preoperative tumor markers were high
with an alpha-fetoprotein (AFP) rate of 210ng/mL (normal
value <6ng/mL), beta-human chorionic gonadotrophin at a
normal rate (2.45mu/mL), Ca 125 rate of 30u/mL (normal
value <35u/mL), and lacticodehydrogenase was at 326u/L
(normal value < 480u/L).
Laparotomy revealed a huge right ovarian mass with
multiple peritoneal granules measuring between 0.2 and
0.5cm. A total hysterectomy, oophorectomy, and omen-
tectomy were performed. Histological examination of the
ovarian mass (weight = 1880g) revealed a teratomatous
tumor,withgrade2immatureareas,showingneuroepithelial
elements. The contra lateral ovary was not involved.
Peritoneal granulations consisted of a mature glial tissue.
Examination of peritoneal ﬂuid did not reveal suspicious
lesions. Postoperatively, the rate of AFP was 76.98ng/mL.2 Case Reports in Medicine
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Figure 1: Postchemotherapy histology: mature teratoma (hema-
t o x y l i na n de o s i ns t a i n×10).
Figure 2: Postchemotherapy histology: mature glial tissue (hema-
t o x y l i na n de o s i ns t a i n×20).
The patient had an immature teratoma on histopathol-
ogy. The histopathological specimen analyzed did not show
aspectsofyolk-sacand/orembryonalcarcinoma.Thecoexis-
tence of an elevated AFP and immature teratoma concluded
to a diagnosis of a nonseminomatous ovarian germ cell
tumor.
Chemotherapy combining cisplatin 100mg/m2 on day 1
and etoposide 120mg/m2 on days 1-2-3, every 21 days, was
administered for 6 cycles with normalization of AFP from
the 4th cycle (1,34ng/mL); other markers were still unre-
markable. Moreover postchemotherapy pelvic CT (6 months
after surgery) revealed a voluminous pelvic mass 25 × 21 ×
11.5cm containing calciﬁcations and fatty areas. A second
laparotomywasperformed,revealingahugeabdominopelvic
mass and multiple peritoneal implants, and the surgical
procedure had consisted of an optimal cytoreduction.
Surgical pathology consisted of benign mature teratoma
with no neuroectodermal component (Figure 1), associated
with peritoneal gliomatosis (Figure 2). The patient remained
in good control 60 months after the second intervention
with regular monitoring of markers and abdominopelvic
computed tomography scan.
3. Discussion
GTS and “chemotherapy retroconversion”, deﬁned as con-
version of a metastatic immature teratoma into a metastatic
mature teratoma as a result of chemotherapy are two names
denoting the same entity; the concordance of these two
entities has been recently conﬁrmed by Amsalem et al. [4].
The GTS rarely occurs in association with OGCT but
was more commonly described in males treated for testicular
nonseminomatous germ cell tumors.
Two etiopathogenic mechanisms for the occurrence of
this syndrome were discussed [1]: selective destruction of the
malignant component of immature teratoma as a result of
chemotherapy and persistence or progression of chemore-
sistant benign mature teratomatous elements. The second
hypothesis is spontaneous diﬀerentiation of malignant cells
into benign tissues.
Tangjitgamol et al. [5] had found, after a review of the
English literature, 30 cases of GTS. Only one feature seemed
to predispose to the occurrence of a GTS: the presence
of mature teratoma at the initial histological examination,
found in 62.5% of patients who developed ovarian GTS.
This syndrome may also cause confusion with a pro-
gression or recurrence of a germ cell tumor because of the
increase in tumor volume during chemotherapy, hence the
importance of recognizing it. Moreover patient’s eventual
treatment and prognosis are highly dependent on the timing
of diagnosis because detection of GTS in a delayed stage
results in a more extensive surgical dissection with a higher
associated risk of adjacent organ injury.
In the case studied, the patient had initially a huge
abdominal mass with a high rate of AFP, conﬁrming the
malignancyofthegermcelltumor.ThediagnosisofGTSwas
made in view of the increase in tumor size after chemother-
apy and normalization of AFP. This diagnosis was conﬁrmed
bythepostchemotherapypathologicalexaminationrevealing
a benign mature teratoma, without malignant germ cells.
Teratoma did not include a neuroectodermal component.
Anoptimalcytoreductionistherecommendedtreatment
of GTS, because of the risk of obstructive complications
and rapid increase in tumor volume, which could lead to
inoperability [3, 5]. Chemotherapy and radiotherapy do not
seem to have a role in the treatment of GTS because of its
benignity [5].
Careful monitoring is required due to the high risk
of recurrence until 10 years after initial diagnosis [6–
8], particularly in cases with signiﬁcant residual tumor.
Recurrence will also be eligible for surgery.
The prognosis of this benign entity remains favorable,
with a survival of up to nine years in completely resected
cases [9].
About 95% of ovarian germ cell tumors are represented
by pure teratoma, in comparison to 4% of testicular germ
cell tumors. Since ovarian teratomas are derived from benignCase Reports in Medicine 3
germ cells, immature elements represent the evolution of
a malignant clone [10]. Immaturity usually manifests as
immature neuroepithelium that develops within a pre-
existing teratoma [10].
Prognosis for immature teratoma of the ovary is related
to stage and grade of the tumor. The 2-year disease-free
survival for grade 2 immature teratoma is about 50%.
Recurrence can be minimized by postoperative adjuvant
therapy with bleomycin, etoposide, and cisplatin (BEP) if
the tumor is of grade 2 or 3. Second aggressive debulking
is limited to patients having a growing teratoma syndrome
after immature teratoma [11].
Immature ovarian teratomas are associated with
gliomatosis peritonei, a favorable prognostic ﬁnding if
composed of completely mature tissues.
The peritoneal gliomatosis (PG) is a very rare entity,
deﬁned by the implantation of glial tissue in the peritoneal
cavity, omentum, and abdominal lymph nodes. PG occurs
almost exclusively in combination with an ovarian teratoma,
whatever its grade [12].
Two theories have been proposed regarding the patho-
genesis of PG. One of them postulates that the PG is
derived from teratoma associated with the relocation of
cells from the primary tumor through the capsular defect
(spontaneous or surgical) or by lymphogenous metastatic
spread [13]. The other theory suggested [14–19] that glial
implants develop from normal cells having undergone a
metaplastic process in response to an unknown endogenous
or exogenous neoplastic stimulus. The latter seems to be the
most appropriate.
Molecular studies have been performed to better under-
stand the relationship between an ovarian teratoma and PG.
Best et al. [15] performed a molecular analysis of a patient
diagnosed with immature ovarian teratoma and GP and
demonstrated mutually exclusive genetic diﬀerences among
the tumors, establishing the neoplasms as genetically distinct
from each other, representing multiple independent tumors
rather than true tumor recurrence or spread. Ferguson et al.
[16] studied DNA samples extracted from ovarian teratoma
and glial implants from two patients. They exploited the
unique genetic characteristic of many ovarian teratomas
(containing a duplicated set of maternal chromosomes and
are thus homozygous at polymorphic microsatellite loci),
contrasting with DNA from matched normal or metaplastic
tissue (containing genetic material of both maternal and
paternal origin and are heterozygous at many of these
same microsatellite loci). In these two cases, all implants
and normal tissue showed heterozygosity at each of three
microsatellite loci on diﬀerent chromosomes, whereas the
teratoma showed homozygosity at the same microsatellite
loci,indicatingthatglialimplantsinGPoftenarisefromcells
within the peritoneum, presumably pluripotent M¨ ullerian
stem cells, and not from the associated ovarian teratoma.
By performing the same molecular analysis, Kwan et al.
[17] concluded that PG is genetically unrelated to the associ-
ated teratoma but is probably derived from nonteratomatous
cells, such as through metaplasia of submesothelial cells.
The association of GTS and PG was previously described
by Shefren et al. [20], who reported the case of a patient
with grade III immature teratoma associated with extensive
peritoneal implants of mature glial tissue. The implants
of glial tissue were present during both the initial and
the second-look laparotomy, performed after chemotherapy.
The “chemotherapeutic retroconversion” seems to partici-
pate in the development and progression of the PG, because
GTS and PG are both benign glial implants either in the
peritoneum or ovary.
A review of the literature, reported by Chou et al. [21],
had found 65 cases of PG, which have favorable prognosis
after surgical treatment.
TreatmentofPGisthecompletesurgicalresection,which
has two objectives: conﬁrmation of diagnosis and therefore
the exclusion of malignancy, but also the prevention of
malignant transformation of residual lesions.
Complete excision is often impossible, given the extent
of the lesions, hence the importance of close monitoring of
residual lesions, using imaging such as CT scans.
The presence of a PG at the initial laparotomy may be
predictive of the occurrence of a GTS after chemotherapy
of a germ cell tumor of the ovary [22], hence the value of
an optimal initial surgery to prevent disease progression. A
long-term monitoring is also required.
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